Guardant Health, Inc. announced an agreement with Bayshore HealthCare, a leading home and community healthcare service provider in Canada. This partnership will offer Guardant’s portfolio of precision oncology tests across the continuum of cancer care through Bayshore’s network of clinics.
Bayshore HealthCare provides care to over 350,000 Canadians annually, and this agreement will significantly expand access to advanced cancer testing tools for its providers and patients. The clinics will offer Guardant360 for therapy selection, Guardant Reveal for minimal residual disease (MRD) detection, and the Shield blood test for colorectal cancer screening.
Helmy Eltoukhy, Guardant chairman and co-CEO, stated that this partnership will give Bayshore physicians access to the latest molecular profiling technology to provide a more complete view of cancer. This aims to help develop optimal personalized care plans, improve outcomes, and reduce cancer-related deaths in Canada.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.